retatrutide parkinson clinical trial Lilly Prepares for FDA Filing Following Additional Phase 3 Data in Diabetes, CVD Parkinson's research trial numbers remain

While uncommon, some studies suggest NAION may occur slightly more often in people taking GLP-1 medications

However, cortical bone thickness was decreased in the semaglutide group ( P = 0.032), while no significant changes in bone microarchitecture or biomechanical strength were noted

A proportion of participants in the retatrutide trial discontinued treatment due to gastrointestinal side effects that did not resolve

It's a GLP-1 thing

The entire process, from filling out the intake form to receiving medication at your door, typically takes four to seven days

Connection Between Ozempic and Gallbladder Issues Novo Nordisk issued a product warning in 2022 following several medical studies linking Ozempic usage to gallbladder problems